Generic Definity RT Availability
Last updated on Apr 10, 2025.
See also: Generic Definity
Definity RT is a brand name of perflutren, approved by the FDA in the following formulation(s):
DEFINITY RT (perflutren - injectable;intravenous)
-
Manufacturer: LANTHEUS MEDCL
Approval date: November 17, 2020
Strength(s): 13.04MG/2ML (6.52MG/ML) [RLD]
Is there a generic version of Definity RT available?
No. There is currently no therapeutically equivalent version of Definity RT available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Definity RT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Lipid-encapsulated gas microsphere compositions and related methods
Patent 10,022,460
Issued: July 17, 2018
Inventor(s): Robinson Simon P. & Siegler Robert W. & Onthank David C. & Nguyen Nhung Tuyet
Assignee(s): Lantheus Medical Imaging, Inc.The invention provides, inter alia, improved lipid formulations used to generate lipid-encapsulated gas microspheres, and methods of their use.
Patent expiration dates:
- December 28, 2035✓✓
- December 28, 2035
-
Lipid-encapsulated gas microsphere compositions and related methods
Patent 10,583,207
Issued: March 10, 2020
Inventor(s): Robinson Simon P. & Siegler Robert W. & Onthank David C. & Nguyen Nhung Tuyet
Assignee(s): Lantheus Medical Imaging, Inc.The invention provides, inter alia, improved lipid formulations used to generate lipid-encapsulated gas microspheres, and methods of their use.
Patent expiration dates:
- December 28, 2035✓
- December 28, 2035
-
Methods for making ultrasound contrast agents
Patent 10,583,208
Issued: March 10, 2020
Inventor(s): Robinson Simon P. & Siegler Robert W. & Nguyen Nhung Tuyet & Onthank David C. & Anklekar Tarakeshwar Vishwanath & Van Kirk Charles Chester
Assignee(s): Lantheus Medical Imaging, Inc.Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
Patent expiration dates:
- March 16, 2037✓
- March 16, 2037
-
Methods and devices for preparation of ultrasound contrast agents
Patent 10,588,988
Issued: March 17, 2020
Inventor(s): Robinson Simon P. & Walker Carol & Onthank David C. & Lazewatsky Joel & Nguyen Nhung Tuyet
Assignee(s): Lantheus Medical Imaging, Inc.Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use.
Patent expiration dates:
- May 4, 2037✓
- May 4, 2037
-
Methods for making ultrasound contrast agents
Patent 11,266,750
Issued: March 8, 2022
Inventor(s): Robinson Simon P. & Siegler Robert W. & Nguyen Nhung Tuyet & Onthank David C. & Anklekar Tarakeshwar Vishwanath & Van Kirk Charles Chester
Assignee(s): Lantheus Medical Imaging, Inc.Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
Patent expiration dates:
- March 16, 2037✓
- March 16, 2037
-
Lipid-encapsulated gas microsphere compositions and related methods
Patent 11,395,856
Issued: July 26, 2022
Inventor(s): Robinson; Simon P. et al.
Assignee(s): Lantheus Medical Imaging, Inc. (North Billerica, MA)The invention provides, inter alia, improved lipid formulations used to generate lipid-encapsulated gas microspheres, and methods of their use.
Patent expiration dates:
- December 28, 2035✓✓✓
- December 28, 2035
-
Methods for making ultrasound contrast agents
Patent 11,529,431
Issued: December 20, 2022
Inventor(s): Robinson; Simon P. et al.
Assignee(s): Lantheus Medical Imaging, Inc. (North Billerica, MA)Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
Patent expiration dates:
- March 16, 2037✓
- March 16, 2037
-
Methods for making ultrasound contrast agents
Patent 11,857,646
Issued: January 2, 2024
Inventor(s): Robinson; Simon P. et al.
Assignee(s): Lantheus Medical Imaging, Inc. (North Billerica, MA)Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
Patent expiration dates:
- March 16, 2037✓
- March 16, 2037
-
Methods for making ultrasound contrast agents
Patent 11,925,695
Issued: March 12, 2024
Inventor(s): Robinson; Simon P. et al.
Assignee(s): Lantheus Medical Imaging, Inc. (North Billerica, MA)Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
Patent expiration dates:
- March 16, 2037✓
- March 16, 2037
-
Methods for making ultrasound contrast agents
Patent 12,161,730
Issued: December 10, 2024
Inventor(s): Robinson; Simon P. et al.
Assignee(s): Lantheus Medical Imaging, Inc. (Bedford, MA)Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
Patent expiration dates:
- March 16, 2037✓
- March 16, 2037
-
Methods for making ultrasound contrast agents
Patent 9,789,210
Issued: October 17, 2017
Inventor(s): Robinson Simon P. & Siegler Robert W. & Nguyen Nhung Tuyet & Onthank David C. & Anklekar Tarakeshwar Vishwanath & Van Kirk Charles Chester
Assignee(s): Lantheus Medical Imaging, Inc.Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
Patent expiration dates:
- March 16, 2037✓
- March 16, 2037
More about Definity RT (perflutren)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- Drug class: ultrasound contrast media
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.